Moderna's Covid-19 vaccine shows early promise; shares soar around 20%

Early data from Moderna’s Covid-19 vaccine, the first to be tested in the US, showed that it produced protective anti-bodies in a small group of healthy volunteers, the company said on Monday.
 

The data are from eight people who took part in a safety trial that kicked off in March as the global pandemic caused by the novel coronavirus was spreading.
 

In the trial of 45 volunteers, conducted by the National Institute of Allergy and Infectious Diseases, eight volunteers who got two doses of the vaccine produced protective antibodies roughly on par with people who recovered from a natural infection